1,5-Diamino-3-oxapentane - CAS 2752-17-2

2,2-Oxybis(ethylamine) is a polyethylene glycol (PEG)-based PROTAC linker. 2,2-Oxybis(ethylamine) can be used in the synthesis of a series of PROTACs.

* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.

Molecular Formula
C4H12N2O
Molecular Weight
104.1509

1,5-Diamino-3-oxapentane

    • Specification
      • Purity
        98%
        Appearance
        Colorless to Almost colorless clear liquid
        Storage
        4°C, protect from light; In solvent, -80°C, 6 months; -20°C, 1 month (protect from light)
        Shipping
        Room temperature in continental US; may vary elsewhere.
        IUPAC Name
        2-(2-aminoethoxy)ethanamine
        Synonyms
        2,2'-oxybis-ethanamin; 2,2'-OXYBIS(ETHYLAMINE); 2,2'-OXYDIETHYLAMINE; 2,2'-DIAMINODIETHYL ETHER; 1,5-DIAMINO-3-OXAPENTANE; BIS(2-AMINOETHYL) ETHER; 1,5-DIAMINO-3-OXAPENTANE 98%; 2,2'-Oxybis(ethanamine)
    • Properties
      • Boiling Point
        64 °C/4 mmHg
        Density
        0.961 g/cm3
        InChI Key
        GXVUZYLYWKWJIM-UHFFFAOYSA-N
        InChI
        InChI=1S/C4H12N2O/c5-1-3-7-4-2-6/h1-6H2
        Canonical SMILES
        C(COCCN)N
    • Reference Reading
      • 1. Effectiveness of High-Intensity Interval Training (HIT) and Continuous Endurance Training for VO2max Improvements: A Systematic Review and Meta-Analysis of Controlled Trials
        Zoran Milanović, Goran Sporiš, Matthew Weston Sports Med. 2015 Oct;45(10):1469-81.doi: 10.1007/s40279-015-0365-0.
        Background:Enhancing cardiovascular fitness can lead to substantial health benefits. High-intensity interval training (HIT) is an efficient way to develop cardiovascular fitness, yet comparisons between this type of training and traditional endurance training are equivocal. Objective:Our objective was to meta-analyse the effects of endurance training and HIT on the maximal oxygen consumption (VO2max) of healthy, young to middle-aged adults.
        2. Cataract prevalence and prevention in Europe: a literature review
        Elena Prokofyeva, Alfred Wegener, Eberhart Zrenner Acta Ophthalmol. 2013 Aug;91(5):395-405.doi: 10.1111/j.1755-3768.2012.02444.x.Epub 2012 Jun 20.
        This literature review is aimed at the evaluation of the potential for cataract prevention in Europe. It was performed using PubMed with Mesh and free-text terms. Studies included were (i) performed on a population of Caucasian origin at an age range of 40-95 years, (ii) cataract was clinically verified, (iii) drug record of prescriptions, their indication, a record of every diagnosis, dosage and quantity of prescribed medicine were available, (iv) sample size >300 and (v) published between 1990 and 2009. The results of 29 articles were reviewed. Former [3.75 (2.26-6.21)] or current smoking [2.34 (1.07-5.15)], diabetes of duration >10 years [2.72 (1.72-4.28)], asthma or chronic bronchitis [2.04 (1.04-3.81)], and cardiovascular disease [1.96 (1.22-3.14)] increased the risk of cataract. Cataract was more common in patients taking chlorpromazine during ≥90 days with a dosage ≥300 mg [8.8 (3.1-25.1)] and corticosteroids >5 years [3.25 (1.39-7.58)] in a daily dose >1600 mg [1.69 (1.17-2.43)]. Intake of a multivitamin/mineral formulation [2.00 (1.35-2.98)] or corticosteroids [2.12 (1.93-2.33)] also increased the risk of cataract. Corticosteroids applied orally [3.25 (1.39-7.58)], parenteral [1.56 (1.34-1.82)] or inhalational [1.58 (1.46-1.71)] lead to cataract more frequently than those applied topically: nasal [1.33 (1.21-1.45)], ear [1.31 (1.19-1.45)] or skin [1.43 (1.36-1.50)]. Outpatient cataract surgery was negatively associated with total cataract surgery costs, and chlorpromazine, corticosteroids and multivitamin/mineral formation increase the risk of posterior subcapsular cataract dependent on dose, treatment application and duration. This review presented a comprehensive overview of specific and general cataract risk factors and an update on most recent experimental studies and randomized control trials directed at cataract prevention.
Bio Calculators
Stock concentration: *
Desired final volume: *
Desired concentration: *

L

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2

* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O c22h30n40
g/mol
g
Related Products
BOC Sciences Support

Please contact us with any specific requirements and we will get back to you as soon as possible.


  • Verification code

We invite you to contact us at or through our contact form above for more information about our services and products.

USA
  • International:
  • US & Canada (Toll free):
  • Email:
  • Fax:
UK
  • Email:
Inquiry Basket